|
CEL-SCI hopes to make L.E.A.P.S. and bounds in preventing and treating deadly diseases. Its L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology modulates T-cells and may lead to synthetic vaccines for herpes, viral encephalitis, smallpox, and other diseases; the National Institutes of Health is testing CEL-1000 (a compound developed using L.E.A.P.S. technology) as a potential avian flu vaccine. The firm's lead drug candidate, however, is Multikine, which might make tumors more susceptible to radiation therapy and help a patient's body produce tumor-fighting antibodies. Multikine is undergoing clinical trials for the treatment of head and neck tumors.
|
| | | Contact Information | |
Address: |
8229 Boone Blvd., Ste. 802
Vienna, VA 22182
| | Phone: | 703-506-9460 | | Fax: | 703-506-9471 |
|
| Financial
Highlights | | Fiscal Year End: | September | | Revenue (2008): | 0.00 M | | Revenue Growth (1 yr): | (-91.10%) | | Employees (2008): | 30 | | Employee Growth (1 yr): | 15.40% |
|
|
Key People
| | • |
Chairman and President:
Maximilian de Clara
| | • |
CEO, Treasurer, and Director:
Geert R. Kersten
| | • |
SVP Operations and Secretary:
Patricia B. Prichep
|
|
|
